Archive | April, 2024

Hot Investor Mandate: VC Firm Invests in Seed to Series B Life Science Technologies Addressing Underserved Populations and Geographies in the US

25 Apr

A venture capital firm based in Seattle, Washington is looking to make another 10 investments with its current fund. The fund primarily invests in Series A, but is open to Seed and Series B. The typical check size is between $250K – $2M, dependent on the stage of investment. The firm identifies themselves as very involved investors and will not invest until they see a clear path through which they can add value to the company. The firm has a strong diversity lens and looks for diverse teams including women and individuals of different backgrounds. The firm invests in USA based companies. 

 
The firm will invest in therapeutics, diagnostics, medical devices, and digital health. The fund is particularly interested in companies targeting health related issues impacting underserved populations and geographies, such as diabetes, cancer, femtech, and cardiovascular health. The fund looks for therapeutics companies to be within 6 months of submission for phase 1 trials. The fund will look at medical device companies within 6 months of 510(k) approval. The fund also requires that there is an MVP and customer attraction but does not require there to be revenue. Similarly with diagnostics, the firm requires an MVP but does not require revenue. The fund does require digital health companies to have revenue. 
 
The firm prefers to work with management teams with prior experience with startups or within the industry, but is not a firm requirement. The firm will lead or co-invest. The firm requires a board seat when leading rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Europe-Based VC Looks to Invest in Pre-Seed to Series A Rounds for Pre-Clinical Stage Drug Development Companies

25 Apr

A firm based in Europe raised a second fund with €60M under management for Pre-Seed, Seed, and Series A investments. The fund is backed by a majority of private investors with the support of a number of institutional investors such as European Investment Fund (EIF). The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is looking for investments across Europe. 
 
The firm invests in the biotech sector, exclusively in the drug development space, and with a preference for Advanced Therapies and Synthetic Biology. The firm has an interest in cutting edge technology, and it specializes in tech transfer opportunities. The firm is agnostic indication-wise and will invest in projects in preclinical stage that have reached an in vivo proof of concept in an animal model relevant for the disease for which the therapy is being developed. 
 
The firm looks for companies with a scientific founder, and preferably a C-Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Confirmed Early-Stage Investors Attending RESI Europe in June

18 Apr

By Faith Patenaude, Investor Research Analyst, LSN

Faith

Life Science Nation (LSN) is thrilled to announce the third RESI conference of the year, which will take place in Barcelona, Spain. We invite you to join us in person on Monday, June 17th, at the Hilton Diagonal Mar Barcelona, and virtually on June 18th-19th. Monday’s schedule includes engaging entrepreneur workshops, insightful investor panels, and our highly favored Innovator’s Pitch Challenge (IPC). One-on-one partnering opportunities will be available throughout the three-day event.

RESI Europe stands as an exceptional platform for early-stage life science companies, providing unparalleled opportunities to engage and connect with a diverse array of European and global investors. The LSN investor research team has been diligently working to invite investors, including CVC, angel groups, family offices, venture capital funds, big pharma, and more. Each investor has undergone thorough vetting to ensure alignment with company profiles, guaranteeing a distinctive edge over other conferences and fostering high-caliber attendance. RESI’s partnering platform welcomes the opportunity for you to connect with investors with aligned interests and of best fit. RESI offers an outstanding chance for early-stage startups, service providers, and investors to cultivate meaningful connections and broaden their network within the life science sector.

Save up to €500 with our super early bird rate – ending tomorrow, Friday April 19th. Sign up now and join the featured investors below.

CI04182024

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Decoding the Mysteries Behind the Low Success Rate of Life Science Startups

18 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The life science industry is a hotbed of innovation and groundbreaking research, but its startup success rate paints a sobering picture, ranging from 1 to 5%. What lies behind this alarming statistic? As CEO of Life Science Nation (LSN) and the mastermind behind the Redefining Early Stage Investments (RESI) partnering conference, I have witnessed firsthand for over a decade the multifaceted complexities that plague the entrepreneurial journey and produce these dismal metrics for life sciences startups. Below is a table that outlines the challenges for startups launching a fundraising campaign.

Critical Pitfalls Misunderstanding the Ante into the Game
Subpar Ideas Not all ideas are created equal. Some startups force-fit innovation without validating market fit, others create solutions in search of a problem without a clue about the business model, and still, others pay scant attention to scaling customer acquisition and channel. Startups require evidence of a current unmet need and a market.  
Inexperienced Teams Startup teams without experience navigating the complexities of launching and scaling a business often find themselves ill-equipped to overcome the challenges. This often leads to costly mistakes that can cause the business to fail, despite the potential merit of the technology.
Mismatched Skill Sets CEOs sometimes fall into the trap of hiring team members who mirror their skill sets rather than seeking complementary expertise, leading to gaps in essential capabilities.  
Underestimating Scale-Up Challenges Creating a prototype is a crucial step and presenting initial validating data does not always translate to success scaling up from proof of concept to full-fledged products.
Navigating Support Ecosystems  The landscape of support networks for startups, including incubators, accelerators, and innovation clusters, can be a double-edged sword. While valuable resources abound, not all mentors and advisors possess the practical experience to guide startups effectively. Hence we see cookie-cutter, non-personalized pitch decks that cover “problem, solution, addressable market,” providing no insight into the founder,  team, and genesis of technology.  
Preparing and Executing a Fundraising Campaign  Startups need a compelling story, a global target list of at least 800 partners to go after, a CRM to organize and manage the list, and someone who understands social media and is a people person to set up meetings and schedule follow-ups. It takes 9-18 months if you are lucky. 

Despite these challenges, I remain optimistic about the future of life science entrepreneurship. The key lies in mastering the art of fundraising—a process that demands a nuanced understanding of global markets, investor relations, and strategic messaging. Launching a successful fundraising campaign requires meticulous planning and execution. Cultivating a targeted list of potential partners and investors tailored to the startup’s stage of development and product offering is crucial. This approach starkly contrasts the indiscriminate spamming tactics often employed by ill-prepared startups.

Herein lies the significance of initiatives like Life Science Nation (LSN) and the RESI partnering series. These platforms provide invaluable resources and networking opportunities for startups seeking to navigate the complex landscape of fundraising and industry partnerships. LSN offers Entrepreneurial Education Classes for Preparing and Executing a Successful Global Partnering Campaign. A database of investors and licensing partners that fit your stage of development and product and can be integrated with your CRM, and the international RESI conference series that get you out of your region and into the international marketplace where you can attend in-person meetings and also virtual meetings with a bevy of potential investor from around the world.

Mastering the Art of Fundraising

Securing funding necessitates a nuanced understanding of global markets, investor relations, and strategic messaging. LSN products combined with the RESI partnering series offer invaluable resources and networking opportunities for startups navigating the complex fundraising landscape. By embracing strategic fundraising methodologies, startups can amplify their chances of success amidst the industry’s burgeoning innovation.

Closing the Funding Gap in Europe 

18 Apr

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

We have all heard that 2023 was a difficult year for early-stage funding. One theory is that pharma M&A activity lagged and reduced the incentive for investment into new life sciences funds, combined with the general expectation that a global recession was coming, leading VCs to invest mainly in their current portfolio companies and not so much into new ventures.

Thankfully, the recession didn’t materialize, and some pharma execs point to favorable conditions that connote an uptick in M&A activity that will bring a kind of trickle-down effect and benefit the early-stage folks. The impressions I have gathered at this year’s first two RESI conferences have been upbeat about the months ahead.

In Europe, I have always been impressed by the government-backed grant and other funding programs available in each country to help the earliest startups get off the ground. These programs are augmented by excellent EU initiatives like Horizon and EIT. But what happens when European biotech and MedTech startups need to raise larger amounts to move their technologies along on the road to commercialization?

That’s where companies hit a wall; there isn’t enough venture capital on the old continent to fund all the fantastic technologies being developed. A European investor recently told me about one of his very successful portfolio companies that was at a stage where they needed to raise a significant round. Having difficulty finding sufficient co-investors in Europe, they eventually brought in a US investor to complete the round. This was only possible thanks to the European and US investors already having a relationship.

At LSN it has long been our goal to facilitate cross-border relationships, not only between companies and investors, but also between investors from different regions or countries. RESI Europe – Barcelona on June 17-19, 2024 is shaping up to be an especially international gathering. Hope to see you there!

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Hot Investor Mandate: VC With US & China Offices Invests Up to $8M in Early-Stage Therapeutics, Devices, Diagnostics in US and Europe

18 Apr

An investment firm headquarters in China with offices in the US focuses on early-stage investments in life science and healthcare sectors. The firm typically engages in pre-A to series B financing rounds, with initial investment sizes ranges from $500k to $8M, and potential for follow-on investments. The firm looks for opportunities mostly in Europe, and in the US and UK as well. The firm is open to both leading and co-investing. 
 
The firm is interested in therapeutics, medical devices and diagnostics. The firm is open to looking at digital health, AI -related companies but has not invested in one yet. The firm is opportunistic in terms of subsectors and indications. Some areas of interest include immunology, immuno-oncology, CNS disorders and kidney-related diseases. For therapeutics, the firm is open to looking at companies from phase I to beyond, particularly those with proof of concepts or clinical data validating their technologies. For medical devices and diagnostics, the firm tends to look for more mature companies, with product or prototype ready and as well as plans for regulatory approvals. 
 
The firm does not have specific requirements for a company’s management team but prefers to work with founding teams that have entrepreneurial experiences previously. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Europe-Based PE Firm Looks for Therapeutics and Medical Device Companies Globally, Investing €1-20M in Mostly Companies Based in Europe

18 Apr

The firm is a Private Equity firm that was founded in 2001 and based in Paris, France. The firm controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment and is also highly interested in the in-licensing of early stage assets and technologies. The firm has an 8 year period to exit and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France.  For in-licensing opportunities the firm is willing to look globally. 
 
The firm Is currently most interested in companies developing Therapeutics and Medical Devices and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has strong interest in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space the firm has a strong preference for investing in cardiovascular devices but considers other opportunities as well. The firm looks to invest in very early stages of company development generally when lead assets are preclinical and technologies are still in development. 
 
The firm looks to make seed investments as well as being involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

← Older Entries
Newer Entries →